Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomised Controlled Trials.

CONCLUSIONS: Up to 64 weeks of tildrakizumab was well-tolerated, with low rates of serious TEAEs, discontinuations due to AEs, and AEs of clinical interest. This article is protected by copyright. All rights reserved.
PMID: 29742274 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - May 9, 2018 Category: Dermatology Authors: Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaci D, Li Q, Cichanowitz N, Green S, La Rosa C Tags: Br J Dermatol Source Type: research